When you think about the surprising success of the Nasdaq 100 index this year, the first things that naturally come to mind are tech powerhouses like Google, Apple and Microsoft. But you’ve got a leave a little room for the love of biotech too, and my favorite name there is Gilead Sciences.
The immunology specialist has really proven immune to selling for most of its life in the public arena, as it is one of the most successful stocks of any type of the past 10 years, with 2,075% capital appreciation stemming from steadfast invention and marketing of biotech therapies.
Pushing shares to a new high in the past week, though, were positive vibes at the 58th Annual Meeting of the American Society for the Study of Liver Disease currently taking place in Boston. Just in case you couldn’t attend, or haven’t checked out the abstracts, let me be the first to inform you that folks got pretty excited about a previously little-known compound being tested by Gilead with the exotic name GS-9190. It's a polymerase inhibitor therapy for hepatitis C that suddenly shows a lot of promise.
Read More...
